Skip to the page
pepts.wiki

We are not doctors and nothing here is medical advice. Always consult a medical professional first. Why we say this

Animal and cell studiesStub

Livagen

Short synthetic peptide (Khavinson series)

A short synthetic peptide from the Khavinson bioregulator series, described in that literature in relation to the liver. Published work is mostly cell and animal studies from one research group.

Reconstitution calculator

At a glance

Animal and cell studies

The published evidence is from animals and cells. Little or nothing is published from controlled trials in people.

This page is a stub

The wiki has this compound's identity from the My-Pepts library, its standing, and what PubMed holds for it. The article, with its studies read and cited, is not written yet. Until it is, the counts below say how much research exists, not what it found.

How strong is the evidence

How far it has climbed

Every medicine climbs the same ladder. Most compounds never reach the top, and where one stands says how much its claims can carry.

  1. Licensed medicine

    A regulator has reviewed the trials and licensed it for a named use.

  2. Phase 3

    Large randomized trials, often thousands of people, against placebo or a standard treatment.

  3. Phase 2

    Mid-sized trials that measure dose against effect in people with the condition.

  4. Phase 1 and early human studies

    First studies in people: safety, and how the body handles it.

  5. Cells and animals: Livagen

    Laboratory and animal work. An animal result is not a result in people.

18
papers on PubMed
13
of them in people
0
randomized trials
0
reviews

A count says how much has been published, not what it found. Counted on PubMed: 2026-11-16

Handling and reconstitution

From powder to a measured sample

The same four steps for any lyophilized vial. Laboratory handling, not use in a person.

  1. 1. Read the vial

    The label gives the mass of peptide in the vial, in milligrams. That number is the start of every calculation.

  2. 2. Add the diluent

    A measured volume of diluent goes in slowly, down the glass. Swirl gently; shaking can damage a peptide.

  3. 3. Work out the strength

    Concentration is mass divided by volume: 10 mg in 2 mL is 5 mg per mL.

  4. 4. Measure the sample

    Volume is the mass wanted divided by the concentration. On a U-100 syringe, 1 mL is 100 units.

The calculator below does the arithmetic and shows its working.

As powder

General practice for lyophilized peptides: keep the sealed vial frozen or refrigerated, dry and away from light, and follow the supplier's certificate of analysis.

In solution

Once in solution a peptide is kept refrigerated and used within the period the supplier states. A vial drawn from more than once needs a preserved diluent such as bacteriostatic water.

This is general practice for lyophilized peptides, not data on Livagen itself. The batch's certificate of analysis and the supplier's sheet are the facts to go by. More on storage

Reconstitution calculator

Opens on vial sizes common for research peptides. Change any number. How the arithmetic works

Draw to

10 units

0.1 mL on a U-100 syringe

Concentration
2.5 mg/mL
Each unit holds
25 mcg
Samples in the vial
20
Sample
250 mcg

5 mg in 2 mL is 2.5 mg/mL. 250 mcg of that is 0.1 mL, which reads as 10 units. This is arithmetic for a vial of Livagen; no amount here is a recommendation.

Livagen: on PubMed

What PubMed held for Livagen on November 16, 2026. A count says how much a compound has been studied, not what the studies found: how to read these numbers.

18
papers
13
in humans
0
clinical trials
0
randomized trials
2012: 0 papers122013: 1 papers2014: 2 papers142015: 0 papers2016: 0 papers162017: 1 papers2018: 0 papers182019: 0 papers2020: 1 papers202021: 0 papers2022: 0 papers222023: 1 papers2024: 0 papers242025: 0 papers2026: 0 papers so far26
Papers per year, 2012 to 2026. The most in one year: 2.

Most relevant on PubMed

Listed by PubMed's own relevance ranking, trials and reviews first. The wiki has not read these into the article unless they are also among its sources.

  1. [Genomic instability in atherosclerosis]

    StudyDzhokhadze TA, Buadze TZh, Gaiozishvili MN, et al. Georgian medical news, 2014. PMID 25541832

  2. Anti-aging peptide bioregulators induce reactivation of chromatin

    StudyLezhava T, Monaselidze J, Kadotani T, et al. Georgian medical news, 2006. PMID 16705247

  3. Activation of pericentromeric and telomeric heterochromatin in cultured lymphocytes from old individuals

    StudyLezhava T, Jokhadze T Annals of the New York Academy of Sciences, 2007. PMID 17460203

  4. Tissue-specific effects of peptides

    StudyKhavinson VK Bulletin of experimental biology and medicine, 2001. PMID 11713572

  5. [Effect of peptide bioregulator and cobalt ions on the activity of NORs and associations of acrocentric chromosomes in lymphocytes of patients with hypertrophic cardiomyopathy and their relatives]

    StudyGeorgian medical news, 2014. PMID 25341254

  6. Effects of Livagen peptide on chromatin activation in lymphocytes from old people

    StudyKhavinson VKh, Lezhava TA, Monaselidze JG, et al. Bulletin of experimental biology and medicine, 2002. PMID 12533768

Search used: ("Livagen"[tiab]). Run it on PubMed

Research links

Also in Bioregulators